Depression and Anxiety in Peripheral Artery Disease: Hidden Drivers of Worse Outcomes

Why Are Depression and Anxiety So Common in Peripheral Artery Disease?

Peripheral artery disease (PAD) is caused by atherosclerotic narrowing of the arteries supplying the legs, leading to symptoms ranging from intermittent claudication to critical limb ischemia. According to the American Heart Association, PAD affects more than 200 million people globally and shares its major risk factors — smoking, diabetes, hypertension, and dyslipidemia — with coronary and cerebrovascular disease. What is often overlooked is that these same risk factors, together with chronic pain, functional limitation, and social isolation, set the stage for mood and anxiety disorders.

Studies summarized in the AHA statement suggest that depression affects roughly one in three people living with PAD, and anxiety disorders are similarly common. Biological mechanisms likely include systemic inflammation, autonomic dysregulation, and endothelial dysfunction, which are implicated in both atherosclerosis and mood disorders. Psychosocial factors — fear of amputation, loss of independence, and reduced ability to work — further compound the burden, creating a bidirectional relationship in which mental health problems and vascular disease reinforce one another.

How Do Depression and Anxiety Affect PAD Outcomes?

Evidence reviewed by the AHA indicates that depression and anxiety in PAD are not benign comorbidities. They are associated with reduced adherence to guideline-directed medical therapy, lower participation in supervised exercise programs, continued smoking, and poorer glycemic and blood pressure control. Over time, these behavioral pathways translate into measurably worse clinical outcomes, including higher rates of major adverse cardiovascular events, repeat revascularization, amputation, and all-cause mortality.

Depression also appears to blunt the benefits of structured PAD therapies. Patients with significant depressive symptoms walk shorter distances on treadmill testing, report more severe claudication, and are less likely to complete cardiac or vascular rehabilitation. Anxiety, particularly when tied to fear of movement-induced pain, can lead to avoidance of the very walking exercise that is proven to improve functional capacity. Recognizing this interplay is central to the AHA's call for integrated vascular and mental health care.

What Should Clinicians and Patients Do Differently?

The AHA scientific statement calls for systematic mental health screening at PAD diagnosis and at key transitions such as after revascularization or amputation. Validated tools like the PHQ-9 for depression and GAD-7 for anxiety can be integrated into vascular clinic workflows. When symptoms are identified, treatment options include cognitive behavioral therapy, selective serotonin reuptake inhibitors (with attention to cardiovascular safety profiles), and structured exercise programs, which have antidepressant effects in their own right.

For patients, the practical message is that leg symptoms and mood symptoms should be discussed together with their care team. Supervised exercise therapy remains a cornerstone of PAD treatment and can improve both walking ability and psychological wellbeing. Smoking cessation, statin therapy, antiplatelet treatment, and aggressive management of diabetes and hypertension protect both the vascular system and, indirectly, the brain. Treating PAD as a whole-person condition — rather than a purely mechanical plumbing problem — is increasingly seen as essential to improving long-term outcomes.